You just read:

IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy

News provided by

Janssen Biotech, Inc.

19 Jan, 2017, 07:05 ET